Virginie Vidal Selected Research

temelimab

1/2019	A High-dose Pharmacokinetic Study of a New IgG4 Monoclonal Antibody Temelimab/GNbAC1 Antagonist of an Endogenous Retroviral Protein pHERV-W Env.
9/2016	A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis - Rationale and design.
1/2016	Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: A Phase 1 study.
12/2012	GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Virginie Vidal Research Topics

Disease

4	Multiple Sclerosis 01/2019 - 12/2012
1	Drug-Related Side Effects and Adverse Reactions 01/2019
1	Sclerosis 01/2016

Drug/Important Bio-Agent (IBA)

4	temelimabIBA 01/2019 - 12/2012
4	Monoclonal AntibodiesIBA 01/2019 - 12/2012
4	Proteins (Proteins, Gene)FDA Link 01/2019 - 12/2012
1	Immunoglobulins (Immunoglobulin)IBA 01/2019
1	Immunoglobulin G (IgG)IBA 01/2016
1	env Gene ProductsIBA 12/2012
1	Toll-Like Receptor 4IBA 12/2012

Therapy/Procedure

1	Immunomodulation 09/2016